The Impact of an Evidence-Based, Behavioral Cervical Cancer Screening Intervention among Women Living with HIV in Ghana (HOPE-inG): A Type 2 Hybrid Effectiveness Implementation Trial
ABSTRACT
Over 69,000 women living with HIV, (WLWH) in Ghana have a six-fold increased risk of developing cervical
cancer1 and require early and frequent cervical cancer screening (CCS).2-4 However, available data in Ghana
show that the CCS rate among eligible women is as low as 2.7%, and there is no evidence that WLWH screen
at higher rates.5 In response to the need to increase the uptake of CCS among WLWH, our team developed a
Home-based self-sampling for cervical cancer Prevention Education (HOPE) intervention. HOPE consists of
HPV self-sampling combined with a 3R (Reframing, Reprioritizing, and Reforming) communication model for
promoting CCS. In a randomized controlled trial (RCT) in Ghana, we demonstrated that HOPE significantly
increased CCS among WLWH (100%) vs routine clinic-based screening (14.64%).8 Participating women found
the self-sampling and 3R communication model acceptable and culturally appropriate.8 High-impact
implementation strategies are needed to integrate and scale up HPV self-sampling into women’s healthcare in
Ghana. We propose to develop and/or adapt implementation strategies to maximize the success of the HOPE
intervention in increasing its health system adoption, patient uptake, and the sustainment of CCS among WLWH.
Our proposed hybrid type 2 effectiveness-implementation RCT trial will leverage existing relationships with
secondary-level health facilities in Ghana. We will select four secondary-level health facilities with comparable
infrastructure and WLWH patient enrollment. Using the Exploration, Preparation, Implementation, and
Sustainment (EPIS) framework,10,11 we will address the following specific aims.
Aim 1: To develop a culturally appropriate, evidence-based health system implementation plan and provider
training content for successful HOPE implementation (Preparation phase). Through nominal group techniques,
we will support engaged stakeholders in selecting, prioritizing, and adapting culturally appropriate
implementation support strategies (ISS) for HOPE. Aim 2: Assess the effectiveness of the HOPE 2.0 intervention
and success of the implementation plan in a hybrid type 2 trial (Implementation phase) We will conduct a hybrid
type 2 effectiveness-implementation RCT to evaluate the impact of implementation strategies. Four HIV
secondary-level clinics will be cluster-randomized 1:1 in a two-arm RCT. Healthcare providers in the intervention
group (IG, Arm 1) will receive evidence-based training validated in Aim 1. After training, trained providers will
recruit WLWH (n = 576) from their HIV facilities and implement HOPE. Providers in the control group (CG, Arm
2) who will not be trained with our ISS materials, will recruit WLWH (n = 576) and implement HOPE in their
clinics. Aim 3: Assess the impact of the implementation plan on the sustainment of the HOPE intervention at
study sites (Sustainment phase). We will assess the impact of HOPE on WLWH screening behaviors and the
impact of strategy material on providers' self-efficacy for implementing HOPE across the study arms.
Public Health Relevance Statement
PROJECT NARRATIVE
Evidence-based HPV self-sampling coupled with the 3R (reframe, reprioritize, and reform) communication model
increases cervical cancer screening and is effective in minimizing the cervical cancer burden among women
living with HIV (WLWH) in Ghana. Implementation strategies to translate the efficacy of HPV self-sampling and
3R model into women’s healthcare in Ghana are needed. We propose to develop and adapt implementation
strategies to maximize the success of the HPV self-sampling and 3R model in increasing its health system
adoption, patient uptake, and the sustainment of cervical cancer screening among WLWH.
NIH Spending Category
No NIH Spending Category available.
Project Terms
2 arm randomized control trialAcquired Immunodeficiency SyndromeAddressAdoptionBehaviorBehavioralCancer BurdenCervical Cancer ScreeningClinicClinicalCollaborationsCommunicationCommunitiesControl GroupsCost AnalysisCountryCoupledDataEffectivenessEligibility DeterminationEnrollmentEvaluationExploration, Preparation, Implementation, and SustainmentFamilyFeedbackFundingGhanaHIVHPV-High RiskHealth PersonnelHealth care facilityHealth systemHealthcareHigh PrevalenceHomeHospitalsHuman PapillomavirusHybridsIndigenousIndividualInfrastructureInterventionInterviewLeadershipMalignant neoplasm of cervix uteriMeasurementMethodsModelingOutcomeParticipantPatient RepresentativePatientsPenetrationPhasePopulationPreparationPrevention educationProviderRandomizedRandomized, Controlled TrialsReportingResearchResourcesRiskSamplingScreening for cancerSelf EfficacySensitivity and SpecificitySiteSocial supportSurveysSystemTeaching HospitalsTechniquesTestingTrainingTranslatingTranslationsVariantWomanWomen's Healtharmcervical cancer preventioncosteffectiveness evaluationeffectiveness researcheffectiveness-implementation RCTeffectiveness/implementation studyeffectiveness/implementation trialefficacy studyevidence basegroup interventionhybrid type 2 trialimplementation interventionimplementation measuresimplementation outcomesimplementation researchimplementation strategyimplementation/effectivenessinnovationinterestlow and middle-income countriesmedically underservedparticipant enrollmentprimary outcomeprogramsrecruitresearch to practiceresponseroutine practicescale upscreeningsuccesstwo-arm trialuptake
No Sub Projects information available for 1U01CA294757-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01CA294757-01
Patents
No Patents information available for 1U01CA294757-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01CA294757-01
Clinical Studies
No Clinical Studies information available for 1U01CA294757-01
News and More
Related News Releases
No news release information available for 1U01CA294757-01
History
No Historical information available for 1U01CA294757-01
Similar Projects
No Similar Projects information available for 1U01CA294757-01